6mo
Discussion Prompt: For solid tumors, do you favor bsAb T‑cell engagers or ADCs for by‑stander killing?
6mo
Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38584159/
New approaches are needed to lower blood pressure (BP) given persistently low control rates. QUARTET USA sought to evaluate the effect of four-drug, quarter-dose BP lowering combination in patients with...
The QUARTET USA trial tested a four-drug, quarter-dose combination pill against standard candesartan in hypertensive adults. Results showed no significant systolic BP difference but improved diastolic BP with comparable safety.
7mo
Ten tips to manage oral anticoagulation in hemodialysis patients with atrial fibrillation - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39439440/
Patients with chronic kidney disease (CKD) have a high incidence and prevalence of atrial fibrillation (AF). While general treatment strategies for AF may largely be transferred to patients with mild...
Patients with advanced CKD and AF face treatment challenges due to high risks of both stroke and bleeding; proposed tips include novel strategies like factor XI inhibitors and left atrial appendage closure.
7mo
Treatment patterns of patients with worsening heart failure with reduced ejection fraction - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38639469/
Major gaps in use of GDMT, particularly combination therapy, remain among US HFrEF patients. These gaps persist during longitudinal follow-up and are particularly large among patients with recent WHFE.
Patients with HFrEF and recent worsening heart failure events receive suboptimal guideline-directed therapy. CHART-HF reveals persistent underuse and low dosing, especially in combination treatments, across care settings.
7mo
Phase 2/3 data show tezepelumab cuts exacerbations by ~70 % across eosinophilic and non‑eosinophilic phenotypes by blocking TSLP — the master cytokine that ignites Th2 and Th17 cascades.
Could one antibody finally cover both T2‑high and T2‑low patients?